Targeting Programmed Cell Death 1 in Ovarian Cancer.
Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland; École Polytechnique Fédérale de Lausanne, Lausanne, Switzerland; and Swiss Institute of Bioinformatics, Lausanne, Switzerland.
Krisztian
K
Homicsko
Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland; and Ludwig Institute Branch at the University of Lausanne, Lausanne, Switzerland george.coukos@chuv.ch.
George
G
Coukos
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D019008:Drug Resistance, Neoplasm / Q000187:drug effects*; D005260:Female; D006801:Humans; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy*; D010051:Ovarian Neoplasms / Q000188:drug therapy*; D061026:Programmed Cell Death 1 Receptor / Q000037:antagonists & inhibitors*; D016879:Salvage Therapy
D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D061026:Programmed Cell Death 1 Receptor